Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Smoking Cessation Counselling
Interventions: Free Help, Free Nicotine message, Spanish: Free help message, Spanish: Free nicotine message; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 4,171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Pancreatic Cancer
Interventions: Rintatolimod; Drug
Lead sponsor: AIM ImmunoTech Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 3
States / cities: Omaha, Nebraska • Canton, Ohio • Seattle, Washington

Conditions: Recurrent Pericarditis
Interventions: Rilonacept, Placebo; Drug
Lead sponsor: Kiniksa Pharmaceuticals (UK), Ltd.; Industry
Eligibility: 12 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 12
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 9 more

Conditions: Healthy
Interventions: PRA052, Placebo; Drug · Other
Lead sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 60 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Avian Influenza, Bird Flu
Interventions: ND1.1, Placebo control; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy Volunteers
Interventions: AZD8683, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bipolar Disorder, Depression
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 42
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 37 more

Conditions: Post Intensive Care Syndrome
Interventions: MIRA; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Persistent Developmental Stuttering
Interventions: Pagoclone; Drug
Lead sponsor: Pharmacology Research Institute; Other
Eligibility: 18 Years to 65 Years
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Riverside, California

Conditions: Rheumatoid Arthritis
Interventions: Fostamatinib disodium (R935788), Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 24
States / cities: La Jolla, California • Palm Desert, California • Hamden, Connecticut + 21 more

Conditions: Prostatic Neoplasms
Interventions: VT-122, Placebo; Drug
Lead sponsor: Vicus Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 16
States / cities: Fayetteville, Arkansas • Santa Rosa, California • Parker, Colorado + 13 more

Conditions: HIV Infections
Interventions: p24CE1/2 pDNA Vaccine, p55^gag pDNA Vaccine, IL-12 pDNA Adjuvant, Placebo, Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device; Biological · Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: San Francisco, California • Decatur, Georgia • Cleveland, Ohio

Conditions: Menkes Disease
Interventions: Long Term Follow-Up; Drug
Lead sponsor: Sentynl Therapeutics, Inc.; Industry
Eligibility: Not listed
Enrollment: 50 participants
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Solana Beach, California

Conditions: Gastroparesis, Diabetic Gastroparesis, Diabetes, Diabetes Mellitus, Delayed Gastric Emptying
Interventions: metoclopramide, Placebo; Drug
Lead sponsor: Evoke Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 65
States / cities: Dothan, Alabama • Huntsville, Alabama • Tucson, Arizona + 56 more

Conditions: Injury, Spinal Cord
Interventions: Neuro-Spinal Scaffold; Device
Lead sponsor: InVivo Therapeutics; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 16
States / cities: Sacramento, California • San Diego, California • Colorado Springs, Colorado + 12 more

Conditions: Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS), Secondary Progressive Multiple Sclerosis (SPMS), Secondary Progressive MS, Non-Active SPMS, Non-Active Secondary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
Interventions: SUN-627, Placebo; Drug · Other
Lead sponsor: Sundance Biosciences, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 7
States / cities: Tampa, Florida • Atlanta, Georgia • Stony Brook, New York + 4 more

Conditions: Major Depressive Disorder
Interventions: desvenlafaxine succinate sustained release, fluoxetine, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 41
States / cities: Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 31 more

Conditions: HIV Infections
Interventions: DPC 817; Drug
Lead sponsor: Pharmasset; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Breast Cancer
Interventions: Fulvestrant, Alpelisib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 34
States / cities: Chandler, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 31 more

Conditions: Head Lice
Interventions: Generic Ivermectin Lotion 0.5%, Sklice® (Ivermectin) Lotion 0.5%, Vehicle Lotion; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 905 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Non-Small Cell Lung Cancer
Interventions: Osimertinib, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 15
States / cities: Anchorage, Alaska • Los Angeles, California • Orange, California + 11 more

Conditions: Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
Interventions: LY2127399, Placebo every 2 weeks, Placebo every 4 weeks; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 88
States / cities: Anniston, Alabama • Birmingham, Alabama • Gilbert, Arizona + 84 more

Conditions: Multiple Sclerosis
Interventions: BIIB033, Placebo, Avonex; Drug · Other
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 58 Years
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 11
States / cities: Cullman, Alabama • Phoenix, Arizona • Raleigh, California + 8 more

Conditions: Community-Acquired Bacterial Pneumonia (CABP)
Interventions: JNJ-32729463, moxifloxacin, JNJ-32729463 (Open-Label); Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 13
States / cities: Mobile, Alabama • Sylmar, California • Orlando, Florida + 8 more

Search by objective public record fields.

Pragmatic Trial of Text Messages to Recruit Unassisted Tobacco Users Into Quitline Service

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis

A Study of PRA052 in Healthy Volunteers

Safety Study of an Oral Vaccine to Prevent Avian Influenza

AZD8683 Single Ascending Dose Study

Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder

Multi-sensory Intervention Room Application (MIRA) Device in the NSICU

Safety and Efficacy Study of the Investigational Drug Pagoclone, in the Treatment of Persistent Developmental Stuttering (PDS)

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis

Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer

Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA

Long Term Follow-up on Menkes Disease Patients

Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis

Study of Probable Benefit of the Neuro-Spinal Scaffold™ in Subjects With Complete Thoracic AIS A Spinal Cord Injury as Compared to Standard of Care

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

A Study of DPC 817 in HIV-Infected Males

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

Clinical Endpoint Study of Ivermectin 0.5% Lotion

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia